Takeda launches production of the Ixazomib in Yaroslavl

The global pharmaceutical company Takeda announces the opening of a production site at its plant in Yaroslavl for manufacturing Ixazomib, an innovative drug for patients with multiple myeloma.

Ixazomib that is an own proprietary formulation of the company, is available in the form of capsules and is indicated for use in combination with lenalidomide and dexamethasone in patients with multiple myeloma who had received at least one previous therapy line. The drug was registered in Russia in 2017 and launched onto the Russian market in 2018. Now it has the status of an orphan drug.

Andrey Potapov, General Director of Takeda Russia,  Head of the CIS Area:

“The Yaroslavl plant will become the second company site worldwide for the production of the drug with the FDF stage, and the total investments in Russian production was 477 million rubles. The new production capacities will help satisfy the need of Russia and the EEA states in the medicinal product, we will also be able to start ixazomib export, which means that we will increase the availability of the drug for our patients. “

The latest high-tech line with the equipment for labeling is capable to produce 200,000 capsules of the drug per year. A full cycle production of ixazomib including stage of finished dosage form will begin in Yaroslavl at the fourth quarter of 2018.